Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial.
Magdalena PopławskaAgata BlazewiczPublished in: Drug testing and analysis (2018)
Growth hormone releasing peptides (GHRPs) are synthetic peptides with the ability to stimulate human growth hormone (hGH) secretion. Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approval. Nevertheless, they are distributed on the black market and misused by cheating athletes, due to their performance-enhancing effects. Hence, GHRPs have been included in the World-Anti-Doping-Agency's Prohibited List as forbidden substances in sport. Predominantly, analytical methods for detection and unequivocal identification of doping substances are based on mass spectrometry. Therefore, in the present work, a qualitative analysis by liquid chromatography coupled to high-resolution tandem mass spectrometry with a quadrupole time-of-flight analyzer was performed to identify a new heptapeptide (MW = 874.02 Da) - a glycine analogue of GHRP-2. Structure determination using de novo sequencing is described here in detail. The results of this study may indicate a new approach to circumvent a detection of doping practices.
Keyphrases
- growth hormone
- liquid chromatography
- tandem mass spectrometry
- mass spectrometry
- ultra high performance liquid chromatography
- solid phase extraction
- high performance liquid chromatography
- high resolution mass spectrometry
- gas chromatography
- high resolution
- simultaneous determination
- endothelial cells
- loop mediated isothermal amplification
- label free
- drinking water
- healthcare
- transition metal
- molecularly imprinted
- real time pcr
- capillary electrophoresis
- primary care
- health insurance
- bioinformatics analysis
- single cell
- ultrasound guided
- drug induced
- emergency department